Cim LLC purchased a new stake in shares of Pfizer Inc. (NYSE: PFE – Get Rating) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 27,956 shares of the biopharmaceutical company stock, valued at approximately $ 1,508,000.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. State Street Corp raised its stake in Pfizer by 1.8% during the fourth quarter. State Street Corp now owns 284,816,832 shares of the biopharmaceutical company stock worth $ 16,818,434,000 after buying an additional 5,013,651 shares during the last quarter. Geode Capital Management LLC increased its stake in Pfizer by 1.5% in the fourth quarter. Geode Capital Management LLC now owns 101,065,073 shares of the biopharmaceutical company stock valued at $ 5,952,333,000 after purchasing an additional 1,471,980 shares in the last quarter. Norges Bank bought a new stake in Pfizer in the fourth quarter valued at $ 3,351,891,000. Nuveen Asset Management LLC increased its stake in Pfizer by 18.0% in the fourth quarter. Nuveen Asset Management LLC now owns 28,086,667 shares of the biopharmaceutical company stock valued at $ 1,658,518,000 after purchasing an additional 4,278,167 shares in the last quarter. Finally, UBS Asset Management Americas Inc. increased its stake in Pfizer by 2.0% in the third quarter. UBS Asset Management Americas Inc. now owns 23,728,801 shares of the biopharmaceutical company stock valued at $ 1,020,576,000 after purchasing an additional 457,513 shares in the last quarter. 66.50% of the stock is owned by institutional investors and hedge funds.
In other news, SVP Jennifer B. Damico sold 4,000 shares of the business’s stock in a transaction that occurred on Monday, May 16th. The shares were sold at an average price of $ 50.50, for a total value of $ 202,000.00. Following the sale, the senior vice president now owns 15,064 shares of the company stock, valued at $ 760,732. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Jennifer B. Damico sold 4,218 shares of the business’s stock in a transaction that occurred on Tuesday, June 7th. The shares were sold at an average price of $ 53.96, for a total transaction of $ 227,603.28. Following the completion of the sale, the senior vice president now directly owns 10,846 shares in the company, valued at approximately $ 585,250.16. The disclosure for this sale can be found here. Over the last quarter, insiders sold 41,126 shares of company stock worth $ 2,075,003. Corporate insiders own 0.05% of the company stock.
Pfizer stock opened at $ 49.07 on Thursday. Pfizer Inc. has a fifty-two week low of $ 38.82 and a fifty-two week high of $ 61.71. The stock has a market cap of $ 275.33 billion, a PE ratio of 11.25, a price-to-earnings-growth ratio of 0.56 and a beta of 0.76. The firm’s 50-day simple moving average is $ 50.57 and its 200 day simple moving average is $ 52.22. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.13 and a current ratio of 1.39.
Pfizer (NYSE: PFE – Get Rating) last released its earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $ 1.62 earnings per share for the quarter, missing analysts’ consensus estimates of $ 1.66 by ($ 0.04). The company had revenue of $ 25.66 billion during the quarter, compared to analysts’ expectations of $ 24.73 billion. Pfizer had a net margin of 26.97% and a return on equity of 38.29%. The firm’s revenue was up 76.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $ 0.93 earnings per share. As a group, analysts predict that Pfizer Inc. will post 6.61 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Friday, June 10th. Shareholders of record on Friday, May 13th were paid a $ 0.40 dividend. This represents a $ 1.60 dividend on an annualized basis and a yield of 3.26%. The ex-dividend date of this dividend was Thursday, May 12th. Pfizer’s payout ratio is 36.70%.
Several equities research analysts have weighed in on the stock. Berenberg Bank set a $ 50.00 price target on shares of Pfizer in a research note on Friday, May 27th. Citigroup lifted their price target on shares of Pfizer from $ 46.00 to $ 57.00 and gave the company a “neutral” rating in a research note on Tuesday, April 5th. SVB Leerink began coverage on shares of Pfizer in a report on Monday, May 23rd. They set a “market perform” rating and a $ 55.00 price objective for the company. Wells Fargo & Company reduced their price objective on shares of Pfizer from $ 60.00 to $ 55.00 in a report on Wednesday, May 4th. Finally, JPMorgan Chase & Co. set a $ 57.00 price objective on shares of Pfizer in a report on Tuesday, May 3rd. Nine research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $ 57.26.
About Pfizer: (Get Rating)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
Further Reading:
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE: PFE – Get Rating).
Receive News & Ratings for Pfizer Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.
.